Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Boundless Bio, Inc./ 425

Rule 425 Communication · 425

Boundless Bio, Inc.

BOLDNASDAQEQUITYCurrent

Rule 425 Communication

Filed Aug 28, 2026Accepted Aug 28, 2026, 5:26 PM EDTCIK 1782303Accession 0001193125-26-374789
View company →Permanent SEC source ↗
Share

Company context

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. For more information, visit https://boundlessbio.com/.

Current securities

BOLDNASDAQ · EQUITY · Current

Recent company filings

  1. Entry into a Material Definitive AgreementAug 28, 2026
  2. 10-Q filingAug 7, 2026
  3. 4 filingJul 21, 2026
  4. 4 filingJul 16, 2026
  5. 4 filingJul 13, 2026

As-filed source

Primary evidence
As filedOpen full document ↗